Study Design and Participants
A 2026 study published in the Global Spine Journal investigated the relationship between cytochrome P450 2D6 (CYP2D6) metabolizer phenotypes and new persistent opioid use after spine surgery. The research team analyzed data from 3,820 opioid-naive adults who underwent cervical, thoracic, or lumbar fusion or decompression procedures between May 2018 and January 2025. Participants were selected from the All of Us Research Program, which includes whole-genome sequencing data. The study required 365 days of baseline observation, 180 days of postoperative follow-up, and no opioid use 30 to 365 days before surgery. CYP2D6 phenotypes were classified as poor, intermediate, normal, or ultrarapid metabolizers based on genetic profiles.
Key Findings
The study found that 12.0% of participants developed new persistent opioid use, defined as a perioperative opioid fill combined with another fill 90 to 180 days postoperatively. Statistical analysis revealed a significant association between CYP2D6 metabolizer phenotype and persistent opioid use (χ² = 15.30; P = .002). Compared to normal metabolizers, poor metabolizers had a 48% higher adjusted odds of persistent opioid use (OR = 1.48; 95% CI, 1.00–2.18), while ultrarapid metabolizers showed a 50% increased risk (OR = 1.50; 95% CI, 0.89–2.54). Intermediate metabolizers had a minimal increase (OR = 1.05; 95% CI, 0.85–1.30). Among poor metabolizers, those prescribed hydrocodone had a significantly higher risk (OR = 2.15; 95% CI, 1.07–4.32). These findings suggest that genetic variations in CYP2D6 may influence opioid metabolism and long-term use after spine surgery.
Limitations and Context
The study's results are limited by the demographic composition of the All of Us Research Program, which primarily includes European-ancestry participants. The authors noted that extreme-phenotype estimates could not be reliably generalized to other ancestry groups, leaving the risk in non-European populations unknown. Additionally, the study's observational design does not establish causality, and the findings require validation in larger, more diverse cohorts. The authors emphasized that medication-specific replication is necessary before clinical implementation. While the study highlights a potential pharmacogenomic factor in postoperative opioid use, it does not provide definitive guidance for clinical practice.
Implications for Clinical Practice
The research underscores the potential role of CYP2D6 testing in identifying patients at higher risk for persistent opioid use after spine surgery. However, the authors caution against immediate clinical application due to the study's limitations. They recommend further investigation into how genetic factors interact with opioid prescribing patterns and patient outcomes. The findings also highlight the importance of monitoring opioid use beyond the acute postoperative period, as persistent use may impact recovery and require tailored patient counseling. While the study contributes to the growing field of precision medicine, it does not suggest changing current opioid management protocols without additional evidence.
Broader Relevance to Spine Health
This study adds to the understanding of how genetic factors may influence postoperative pain management and opioid dependency. Spine surgery patients often experience prolonged recovery, and opioid use is common, making this a critical area for research. The findings align with broader efforts to personalize medical treatments based on individual genetic profiles. However, the authors stress that more work is needed to translate these results into actionable clinical strategies. The study also raises questions about the role of pharmacogenomics in optimizing pain management and reducing opioid-related complications, which could have implications for chiropractic care and multidisciplinary approaches to spine health.